Course Description
Delve deeper into the history of trauma exposure (e.g., combat-related, sexual-related, violence) and its implications on development of Post-Traumatic Stress Disorder (PTSD) and comorbid alcohol use disorder (AUD). Explore the link between substance use as an attempt to self-medicate trauma symptoms. Lastly, analyze the evidence supporting preferred treatment strategies and risk/benefit of medications for patients with a co-occurring AUD.
Learning Objectives
- Evaluate the prevalence of AUD in patients with PTSD and the impact of these co-occurring conditions on recovery prognosis.
- Analyze the literature describing the pharmacologic management of comorbid PTSD and AUD.
- Determine optimal pharmacotherapeutic treatment plans for patients with PTSD and co-occurring AUD.
Target Audience
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Faculty
View biographical information
Theresa Frey, PharmD, BCPP
Clinical Pharmacy Specialist- Mental Health
William S. Middleton VA Hospital
Madison, WI
Theresa Frey, PharmD, BCPP is a clinical pharmacy practitioner (CPP) in mental health and the residency director of the PGY2 Psychiatric Pharmacy Residency program at the William S. Middleton VA in Madison, WI. She currently she works on the substance use disorders (SUD) team and her CPP role is considered a strong practice in the VA system. Her interest areas include resident/student mentoring, substance use disorders, overdose prevention, and motivational interviewing. She is also a co-chair of the PBM Clinical Pharmacy Practice Office SUD Pharmacy Subject Matter Expert (SME) Workgroup, which supports standardization and expansion of the SUD clinical pharmacy practice in VA.
Faculty Disclosures
This presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: all treatments for Post-Traumatic Stress Disorder (PTSD) mentioned except sertraline and paroxetine. Topiramate, gabapentin, aprepitant, oxytocin, doxazosin, zonisamide are off-label uses for Alcohol use disorder (AUD).
Dr. Frey is not representing the VA in an official capacity in this presentation
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Date: 11/04/2021
ACPE Contact Hours: 1
ACPE Number: 0284-0000-21-054-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: This presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: all treatments for Post-Traumatic Stress Disorder (PTSD) mentioned except sertraline and paroxetine. Topiramate, gabapentin, aprepitant, oxytocin, doxazosin, zonisamide are off-label uses for Alcohol use disorder (AUD).
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.